Company Insights

ALVO customer relationships

Explore interactive graphBrowse insights index

ALVO customers relationship map

Alvotech’s partner-driven monetization: manufacturing biosimilars and selling finished product through global commercialization deals

Alvotech develops and manufactures biosimilars and monetizes primarily by supplying finished biologics to commercial partners under exclusive supply and commercialization agreements, earning revenue from supply contracts, milestone payments and downstream commercial royalties. The company reported trailing twelve‑month revenue of $588.9M and an operating margin of ~34%, underscoring a capital‑intensive manufacturing base paired with partner distribution to reach global markets. For a concise tracker of Alvotech’s partner footprint, visit https://nullexposure.com/.

The commercial model in plain English

Alvotech operates as a specialist supplier and developer: it retains responsibility for development, global clinical activities and manufacturing for many programs, then licenses commercialization rights regionally to large distributors and local pharma companies. That structure gives Alvotech high operational leverage on manufacturing and commercial leverage via partner networks, but it also concentrates counterparty risk across a set of strategic partners who control market access and pricing in their territories.

What the partner list tells investors

The evidence in Alvotech’s public statements and press releases shows a broad, regionally segmented partner strategy: global names (Teva, Sandoz, STADA) for major territories and a long tail of regional distributors (e.g., DKSH, Lotus, Abdi Ibrahim) to penetrate smaller or regulated markets. That combination reduces go‑to‑market friction but creates reliance on partner execution—formularies, launch timing and distributor salesforce effectiveness drive realized revenue.

Customer relationships — every partner called out in filings and press

Below I cover each partner relationship mentioned in the data set with a short plain‑English summary and source reference.

  • Kashiv — Alvotech said it collaborated with Kashiv (and Advanz) on a biosimilar submission referencing Xolair in the EEA. Source: Alvotech 2025 Q3 earnings call (first seen 2026‑03‑07).
  • Ivers‑Lee — Alvotech finalized integration of the Ivers‑Lee acquisition into its financials following the July purchase. Source: Alvotech 2025 Q3 earnings call (first seen 2026‑03‑07).
  • JAMP Pharma Corporation — JAMP markets SIMLANDI in Canada, where Alvotech reports the product is the fastest‑growing Humira biosimilar. Source: Alvotech 2025 Q3 earnings call (first seen 2026‑03‑07).
  • Teva (Teva Pharmaceuticals / Teva Pharmaceutical Industries Ltd.) — Teva is Alvotech’s U.S. commercialization partner for multiple assets, including the Stelara biosimilar (Selarsdi™); Alvotech reports Teva is securing U.S. formulary coverage. Source: Alvotech 2025 Q3 earnings call and Alvotech Q4‑2025 / FY2025 release (GlobeNewswire, Mar 18, 2026).
  • Biogaran — Named as a European commercial partner for Alvotech’s aflibercept (Eylea) biosimilar under a settlement that allocates regional rights. Source: GlobeNewswire release on Alvotech settlement agreement (Jan 29, 2026).
  • STADA / STADA Arzneimittel AG — STADA holds European commercial rights on multiple Alvotech programs; Alvotech cites growing volumes for European launches handled by STADA. Source: Alvotech 2025 Q3 earnings call and press material (Feb 2026).
  • Fuji Pharma Co., Ltd. / Fuji Pharma Ltd. — Identified as Alvotech’s Japan partner for the aflibercept (Eylea) biosimilar. Source: GlobeNewswire settlement announcement (Jan 29, 2026).
  • YAS Holding LLC — Listed as Alvotech’s distributor for Middle East and North Africa in the company’s partner roll‑out disclosures. Source: Alvotech press material on AVT80/Entyvio program (Feb 2026).
  • Dr. Reddy’s (RDY) — Partnering on an oncology program referenced to Keytruda; Alvotech reports continued progress with Dr. Reddy’s. Source: Alvotech 2025 Q3 earnings call (first seen 2026‑03‑07) and FY2026 press items.
  • Sandoz (NVS / SDZNY) — Alvotech entered supply and exclusive finished‑product supply agreements with Sandoz covering multiple biosimilar candidates in Canada, Australia and New Zealand; Alvotech retains development and manufacturing responsibility. Source: GlobeNewswire supply/commercialization announcement (Feb 02, 2026) and follow‑up releases.
  • DKSH — Named as Alvotech’s commercial partner in multiple Asian markets (Taiwan, Hong Kong, Malaysia, Singapore, Indonesia, India, Bangladesh, Pakistan). Source: Alvotech press release listing commercial partners (Feb 2026).
  • Abdi Ibrahim — Identified as Alvotech’s commercial partner for Turkey. Source: Alvotech partner list in press material (Feb 2026).
  • Kamada Ltd. (KMDA) — Named as Alvotech’s partner for Israel. Source: Alvotech press release listing commercial partners (Feb 2026).
  • Mega Labs — Listed among Latin American commercial partners for Alvotech product distribution. Source: Alvotech press material (Feb 2026).
  • Stein — Appears in partner roll‑outs for Latin America distribution alongside other regional distributors. Source: Alvotech press releases and SEC filing reporting partners (Feb–Mar 2026).
  • Libbs — Named as a Latin American commercialization partner in company disclosures. Source: Alvotech partner list in press material (Feb 2026).
  • Tuteur — Included in Alvotech’s Latin American partner roster in public releases. Source: Alvotech partner list (Feb 2026).
  • Saval — Listed as a Latin American commercial partner in Alvotech announcements. Source: Alvotech partner list (Feb 2026).
  • Lotus Pharmaceuticals Co., Ltd. — Designated for multiple Asian markets (Thailand, Vietnam, Philippines, South Korea) in Alvotech’s partner disclosures. Source: Alvotech press material (Feb 2026).
  • Cipla / Cipla Gulf / Cipla Med Pro — Identified as Alvotech’s partner in Australia, New Zealand and parts of Africa/Asia for certain products. Source: Alvotech partner list in company releases (Feb 2026).
  • Yangtze River Pharmaceutical (Group) Co., Ltd. — Named as Alvotech’s distribution partner for China. Source: Alvotech partner disclosures (Feb 2026).
  • Advanz Pharma (Advanz / CXRXF) — Partnered regionally (UK/EEA and other territories) and cited in collaborative submissions (e.g., Xolair candidate); also appears in Eylea partner allocations. Source: Alvotech 2025 Q3 earnings call and GlobeNewswire partner lists (Jan–Feb 2026).
  • Bayer (BAYRY) — Mentioned in connection with a patent settlement and licensing deal relating to AVT06 that clarifies regional market entry and supports Alvotech’s supplier role. Source: analysis note cited on SimplyWall (coverage referencing settlement, Mar 2026).
  • Regeneron (REGN) — Referenced alongside Bayer in the AVT06 patent settlement that structures launch timing and licensing. Source: SimplyWall analyst piece summarizing settlement context (Mar 2026).
  • Kashiv / CHCR — Cited jointly with Advanz as collaborators on an EEA submission to Xolair. Source: Alvotech 2025 Q3 earnings call (first seen 2026‑03‑07).
  • SAZ (STADA symbol) — Used in earnings call references when discussing STADA’s volume growth for Alvotech products in Europe. Source: Alvotech 2025 Q3 earnings call (first seen 2026‑03‑07).
  • NVS (ticker used in filings) — Appears in disclosures referencing Sandoz/Novartis affiliates in supply arrangements; Alvotech will supply finished product under exclusive arrangements. Source: SEC filing coverage and GlobeNewswire (Feb–Mar 2026).
  • SDZNY (Sandoz ticker variants) — Cited in multiple press reports and analyst notes describing the Sandoz supply/commercialization agreements for Canada, Australia and New Zealand. Source: QuiverQuant, GlobeNewswire and analyst pieces (Feb–Mar 2026).

Constraints and operating model signals investors should read together

  • No explicit constraints were provided in the dataset as contractual excerpts; at the company level, the disclosures collectively signal a supplier‑centric contracting posture: Alvotech repeatedly states it will “retain responsibility for development, global clinical activities and manufacturing” while granting commercialization rights regionally. Source: multiple GlobeNewswire and SEC‑filing items (Feb–Mar 2026).
  • Concentration and counterparty risk: a small number of global partners (Teva, Sandoz, STADA) control major launch windows in large markets, so revenue realization depends on those partners’ formulary and commercial execution. Source: Alvotech Q3 earnings call and FY2025 releases (Mar 2026).
  • Criticality to partners: Alvotech’s role as exclusive finished‑product supplier in many agreements makes it a critical upstream vendor; manufacturing problems or FDA/EMA setbacks (e.g., AVT05 facility issues referenced elsewhere) would have immediate commercial impact. Source: company filings and market commentary (Mar 2026).
  • Maturity mix: the partner list contains launched products (Hukyndra, SIMLANDI) and pipeline candidates (Entyvio, Stelara, Eylea), indicating a hybrid of cash‑generating launches and biopharma research risk. Source: Alvotech earnings commentary and press releases (Jan–Mar 2026).

Investment takeaway and next steps

Alvotech’s economics are driven by manufacturing scale and partner monetization; the firm successfully built a global partner web that de‑risks market access but transfers substantial execution risk to commercial partners. Key items for investors to monitor: partner launch timing in the U.S. and EU (Teva, STADA), Sandoz commercialization roll‑outs in Canada/Australia/NZ, and any regulatory or manufacturing updates that could affect supply. For a quick route to company partner data and monitoring, check https://nullexposure.com/.

If you want a focused model of partner exposure by revenue probability and regional launch timing, I can prepare a concise investor memo mapping each partner to likely revenue weightings and key catalysts.

Join our Discord